



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|---|--|
| Applicant: | MICHAEL L. GRUENBERG |) | I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this date. |
| Serial No.: | 08/700,565 |) | |
| Filed: | July 25, 1996 |) | 2/04/97 Date |
| For: | AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE |) |  Stephanie Sharrett |
| Group Art Unit: | Unassigned |) | RECEIVED FEB 13 1997 |
| Examiner: | Unassigned |) | GROUP 1800 |


TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, a PTO-form 1449, the cited reference and a Certification pursuant to 37 C.F.R. § 1.97(e) for filing in connection with the above-identified application.

Since this is a Supplemental Information Disclosure Statement with a Certification, a fee for filing the Statement should not be required. If, however, it is determined that such fees is required in connection with this paper or with any other paper, the Commissioner is hereby authorized to charge the fee for an Information Disclosure Statement and any others fees that may be due under 37 C.F.R. §§ 1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 02-4070. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
BROWN, MARTIN, HALLER & McCLAIN

By: 
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 6870-500B
Address all correspondence to:
Stephanie Seidman, Esq.
BROWN, MARTIN, HALLER & McCLAIN
1660 Union Street
San Diego, California 92101-2926
Telephone: 619/238-0999
EMAIL sseidman@BMHM.com



#4
Dirk Plunkett
6/25/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--|---|--|
| Applicant: | MICHAEL L. GRUENBERG |) | I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: |
| Serial No.: | 08/700,565 |) | Assistant Commissioner for Patents, Washington, D.C. 20231, on this date. |
| Filed: | July 25, 1996 |) | 2/04/97 Date |
| For: | AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE |) | <u>Stephanie Sharrett</u> Stephanie Sharrett |
| Group Art Unit: | Unassigned |) | RECEIVED |
| Examiner: | Unassigned |) | FEB 13 1997 |
| | |) | GROUP 1800 |

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97(c)**

Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97(c) and includes a certification in accordance with 37 C.R.F. § 1.97(e), therefore a fee should not be required. If it is, however, deemed that a fee is due in connection with this Supplemental Information Disclosure Statement or any subsequent Supplemental Information Disclosure Statement, it may be charged to Deposit Account No. 02-4070.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by applicant or applicant's representative that may be material to the examination of the subject application, applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. § 1.97-1.98. Form PTO-1449 and copies of the cited documents are provided herewith.

**U.S.S.N. 08/700,565
Gruenberg
SUPPLEMENTAL IDS**

The document listed on the Form PTO-1449 and supplied herewith is in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, no further explanation of the listed item is necessary.


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application.

In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing information and that it be made of record in the file history of the above-captioned application.

Respectfully submitted,
BROWN, MARTIN, HALLER & McCLAIN

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 6870-500B
Address all correspondence to:
Stephanie Seidman, Esq.
BROWN, MARTIN, HALLER & McCLAIN
1660 Union Street
San Diego, California 92101-2926
Telephone: 619/238-0999
EMAIL sseidman@BMHM.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHAEL L. GRUENBERG

Serial No.: 08/700,565

Filed: July 25, 1996

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE*

Group Art Unit: Unassigned

Examiner: Unassigned

) I hereby certify that this paper is being deposited with
the United States Postal Service as first class mail in an
envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C.
20231, on this date.

2/04/97
Date

Stephanie Sharrett
Stephanie Sharrett

RECEIVED

FEB 13 1997

GROUP 1800

**CERTIFICATION FOR SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT IN ACCORDANCE WITH 37 C.F.R. § 1.97(e)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

- 1) This certification is being made for the Supplemental Information Disclosure Statement accompanying this certification.
- 2) I, Stephanie Seidman, certify that the item of information contained in the accompanying Supplemental Information Disclosure Statement was cited in a communication dated January 17, 1976, from the International Searching Authority (European Office) in connection with PCT International Patent Application No. PCT/US96/12170, which claims priority from the above-referenced application, U.S. Application Serial No. 08/700,565. Thus, this item of information was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the attached Supplemental Information Disclosure Statement.
- 3) The person making this certification is an attorney of record in the above-captioned application and signs below on the basis of information in the attorney's file.



U.S.P.T.O. N. 08/700,565

Grenberg
CERTIFICATION

* * *

Respectfully submitted,
BROWN, MARTIN, HALLER & McCLAIN

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 6870-500B

Address all correspondence to:

Stephanie Seidman, Esq.
BROWN, MARTIN, HALLER & McCLAIN
1660 Union Street
San Diego, California 92101-2926
Telephone: 619/238-0999
EMAIL sseidman@BMHM.com

| | | |
|---|-----------------------------------|-------------------------------------|
| FORM PTO-1449 (Modified) | ATTY. DOCKET NO. 6870-500B | SERIAL NO. 08/700,565 |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | APPLICANT MICHAEL L. GRUENBERG | |
| | FILING DATE July 25, 1996 | GROUP RECEIVED Unassigned |

A circular stamp with the words "MAIL ROOM" at the top, "FEB" in the center, "6" below it, and "1997" to the right. The bottom arc contains "PAT. & T. OFF." and the left arc contains "90".

U.S. PATENT DOCUMENTS

GROUP 1800

FOREIGN PATENT DOCUMENTS

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.